| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | Vorinostat | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.2 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.3 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | 0.042 | 0.3 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.099 | 0.3 |
| mRNA | AZD6482 | GDSC1000 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | tretinoin:carboplatin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.045 | 0.3 |